Theravance Biopharma Inc (TBPH NASDAQ) stock market data APIs
$8.61
0.08(0.9%)
as of January 14, 2025
Theravance Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Prev. Close
8.53
Open
8.61
Volume
180 K
High
8.7
Low
8.46
52 wk Range
7.44-10.44
Market Cap
419 M
Shares Outstanding
49 174 K
Revenue
63 192 K
EPS
-0.059
Beta
0.251
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Theravance Biopharma Inc data using free add-ons & libraries
Get Theravance Biopharma Inc Fundamental Data
Theravance Biopharma Inc Fundamental data includes:
- Net Revenue: 63 192 K
- EBITDA: -38 236 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-12
- EPS/Forecast: -0.23
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Theravance Biopharma Inc News
New
Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long
Theravance Biopharma, Inc. (NASDAQ:TBPH) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Theravance Biopharma, Inc., a biopharmaceutic...
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
A downtrend has been apparent in Theravance Biopharma (TBPH) lately with too much selling pressure. The stock has declined 11.2% over the past four weeks. However, given the fact that it is now in ove...
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
DUBLIN, Jan. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily...
7 Short-Squeeze Stocks That Are Screaming for Speculation
While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it’s time to address this speculative...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
